| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 04/30/2013 | CA2602089C Tigecycline compositions and methods of preparation |
| 04/30/2013 | CA2584122C Loadable polymeric particles for therapeutic and/or diagnostic applications and methods of preparing and using the same |
| 04/30/2013 | CA2571583C Sustained-release composition, process for producing the same and use of the same |
| 04/30/2013 | CA2540869C Spill resistant formulations containing clays |
| 04/30/2013 | CA2523417C Method for storing tumor cells |
| 04/30/2013 | CA2518200C Impregnated powder improving bioavailability and/or solubility and method of production |
| 04/30/2013 | CA2458995C Polynucleotides encoding antigenic hiv type b polypeptides, polypeptides and uses thereof |
| 04/30/2013 | CA2399321C Adenovirus formulations |
| 04/30/2013 | CA2365742C Formulations for amylin agonist peptides |
| 04/25/2013 | WO2013059827A1 Methods and compositions for treating mucositis |
| 04/25/2013 | WO2013059768A1 Therapeutic agents for treating gastrointestinal disorders associated with inflammation of the gastrointestinal tract |
| 04/25/2013 | WO2013059729A1 Tocotrienol compositions |
| 04/25/2013 | WO2013059728A1 Methods and compositions for mitigating proctitis |
| 04/25/2013 | WO2013059702A1 Cerivastatin to treat pulmonary disorders |
| 04/25/2013 | WO2013059676A1 Compositions for reduction of side effects |
| 04/25/2013 | WO2013059631A1 Method and device for administering xinafoate salt of n4-(2,2-difluoro-4h-benzo [1,4] oxazin-3-one) -6-yl] -5-fluoro-n2- [3- (methylaminocarbonylmethyleneoxy) phenyl] 2,4-pyrimidinediamine |
| 04/25/2013 | WO2013059617A1 Liposome compositions and methods of use |
| 04/25/2013 | WO2013059600A1 Removable covering and interactive packaging |
| 04/25/2013 | WO2013059592A1 Excipients for nicotine-containing therapeutic compositions |
| 04/25/2013 | WO2013059528A2 Encapsulated diagnostics and therapeutics in nanoparticles-conjugated to tropic cells and methods for their use |
| 04/25/2013 | WO2013059496A1 Amine cationic lipids and uses thereof |
| 04/25/2013 | WO2013059351A1 Stabilizers for hemostatic products |
| 04/25/2013 | WO2013059295A2 Polymeric depots for localization of an agent to biological sites |
| 04/25/2013 | WO2013059146A1 Solid dosage forms of (s)-ethyl 2-amino-3-(4-(2-amino-6-((r)-1-(4-chloro-2-(3-methyl-1h-pyrazol-1-yl)phenyl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)phenyl)propanoate |
| 04/25/2013 | WO2013059133A1 Lyophilized liposomes |
| 04/25/2013 | WO2013058996A1 Two phase pharmaceutical delivery system |
| 04/25/2013 | WO2013058849A1 Skin therapy systems |
| 04/25/2013 | WO2013058812A1 Targeted delivery to pancreatic islet endothelial cells |
| 04/25/2013 | WO2013058751A1 Cellulose derivatives for enhancing bioavailability of flavonoids |
| 04/25/2013 | WO2013058721A1 Pharmaceutical granules and production method |
| 04/25/2013 | WO2013058674A1 Bicarbonate haemodialysis solution |
| 04/25/2013 | WO2013058511A2 Method for preparing high-purity montelukast sodium salt |
| 04/25/2013 | WO2013058496A1 Taste-masked pharmaceutical composition for oral administration and a process for the preparation thereof |
| 04/25/2013 | WO2013058411A1 Solution for oral administration |
| 04/25/2013 | WO2013058409A1 Sustained-release preparation |
| 04/25/2013 | WO2013058303A1 Medicinal composition |
| 04/25/2013 | WO2013058302A1 Water-soluble soybean polysaccharides and manufacturing process therefor |
| 04/25/2013 | WO2013057747A1 Anti-tumoral compound and relative production process |
| 04/25/2013 | WO2013057569A2 Extended release pharmaceutical composition containing amoxicillin and clavulanic acid |
| 04/25/2013 | WO2013057518A1 Pharmaceutical composition comprising nanocrystals |
| 04/25/2013 | WO2013057461A1 Paste comprising non-steroidal anti-inflammatory |
| 04/25/2013 | WO2013057169A1 Pharmaceutical nanosuspension |
| 04/25/2013 | WO2013056994A1 Improvements in or relating to organic compounds |
| 04/25/2013 | WO2013056993A1 Improvements in or relating to organic compounds |
| 04/25/2013 | WO2013056992A1 Improvements in or relating to organic compounds |
| 04/25/2013 | WO2013056991A1 Method of forming fine particles of a drug substance |
| 04/25/2013 | WO2013056709A1 Nicotine chewing gum with improved utilization of nicotine |
| 04/25/2013 | WO2013056508A1 Pharmaceutical composition regulating blood fat and preparation process thereof |
| 04/25/2013 | WO2013056453A1 Preparation method and application of injection for needleless injection |
| 04/25/2013 | WO2013056327A1 Cleaning solution for contact lenses |
| 04/25/2013 | WO2013056326A1 Controlled release pharmaceutical composition containing naltrexone and topiramate |
| 04/25/2013 | WO2013056298A1 Pharmaceutical compositions of resveratrol |
| 04/25/2013 | WO2013034927A8 Compositions of lopinavir and ritonavir |
| 04/25/2013 | WO2013032643A3 Lipids capable of conformational change and their use in formulations to deliver therapeutic agents to cells |
| 04/25/2013 | WO2013025545A3 Drug delivery systems and method of reducing foal infection by treating mares with gallium salts |
| 04/25/2013 | WO2013025442A3 Concentrated felbamate formulations for parenteral administration |
| 04/25/2013 | WO2013019658A3 Synthetic nanocarriers comprising polymers comprising multiple immunomodulatory agents |
| 04/25/2013 | WO2013016544A3 Templated islet cells and small islet cell clusters for diabetes treatment |
| 04/25/2013 | WO2013013038A3 Doping agents and polymeric compositions thereof for controlled drug delivery |
| 04/25/2013 | WO2013008240A3 Liposomes co-encapsulating a bisphosphonate and an amphipathic agent |
| 04/25/2013 | WO2012173933A3 Activatable nanoprobes for intracellular drug delivery |
| 04/25/2013 | WO2012162629A3 Popcorn shape gold nanoparticle for targeted diagnosis, photothermal treatment and in-situ monitoring therapy response for cancer and multiple drug resistance bacteria |
| 04/25/2013 | WO2012145470A3 Ophthalmic composition with a viscosity enhancement system having two different viscosity enhancing agents |
| 04/25/2013 | WO2012065153A3 Modified immune-modulating particles |
| 04/25/2013 | WO2012021512A8 Erythrocyte-binding therapeutics |
| 04/25/2013 | WO2011061761A3 Pharmaceutical composition for parenteral use comprising mycophenolate mofetil |
| 04/25/2013 | US20130102993 Liposome comprising elastin-like polypeptide and tumor cell targeting material and use thereof |
| 04/25/2013 | US20130102943 Reloadable finishes for textiles and formulations for loading such finishes |
| 04/25/2013 | US20130102898 Liposome including elastin-like polypeptides and use thereof |
| 04/25/2013 | US20130102688 Oil-in-water emulsion composition and method for producing same |
| 04/25/2013 | US20130102676 Controlled release formulations of levodopa and uses thereof |
| 04/25/2013 | US20130102657 Anti-angiogenic compositions and methods of use |
| 04/25/2013 | US20130102588 Tolvaptan solid dispersion and its preparation method |
| 04/25/2013 | US20130102581 Composition and method for treatment of diabetes |
| 04/25/2013 | US20130102564 Topical pharmaceutical composition comprising heparin |
| 04/25/2013 | US20130102555 Method of treating diabetes |
| 04/25/2013 | US20130102548 Pharmaceutical delivery system |
| 04/25/2013 | US20130101673 Compositions and their use in bone healing |
| 04/25/2013 | US20130101672 Nanoconjugates and nanoconjugate formulations |
| 04/25/2013 | US20130101670 Formulations comprising coated fine particles |
| 04/25/2013 | US20130101669 Logical enzyme triggered (let) layer-by-layer nanocapsules for drug delivery system |
| 04/25/2013 | US20130101667 Cyclohexylamines |
| 04/25/2013 | US20130101666 Liposome including elastin-like polypeptide conjugated to moiety containing hydrophobic group, chemosensitizer and anticancer agent and use thereof |
| 04/25/2013 | US20130101663 Soluble tumor necrosis factor receptor (sTNF-R) used as a targeting agent to treat arthritis and other diseases |
| 04/25/2013 | US20130101660 Transdermal delivery patch |
| 04/25/2013 | US20130101659 Cell sheet for myocardial regeneration, method of producing the same, and method of using the same |
| 04/25/2013 | US20130101658 Drug delivery methods, structures, and compositions for nasolacrimal system |
| 04/25/2013 | US20130101656 In situ gelling drug delivery system |
| 04/25/2013 | US20130101651 Dried formulations of nanoparticle-coated capsules |
| 04/25/2013 | US20130101646 Method of Producing Microparticles |
| 04/25/2013 | US20130101645 Methods and compositions for treating mucositis |
| 04/25/2013 | US20130101644 Tocotrienol compositions |
| 04/25/2013 | US20130101643 Methods and compositions for mitigating proctitis |
| 04/25/2013 | US20130101642 Methods and compositions for treating oral mucositis |
| 04/25/2013 | US20130101640 Etanercept Formulations Stabilized with Combinations of Sugars and Polyols |
| 04/25/2013 | US20130101639 Bone semi-permeable device |
| 04/25/2013 | US20130101638 Bone semi-permeable device |
| 04/25/2013 | US20130101632 Nanoparticulate formulations of mithramycin or mithramycin analogues for treating cancer |
| 04/25/2013 | US20130101609 Irradiated biodegradable polymer microparticles |
| 04/25/2013 | US20130101525 Vitamin formulation |